13F Holdings
中文EN

CPMD CANNAPHARMARX, INC.

Pharmaceutical Preparations · OTC · SEC CIK 1081938 · Fiscal year ends 12/31

Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY24.8%
TTM net income YoY-100.1%
TTM EPS YoY33.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin-88.8%
Operating margin-170.1%
Net margin-666.2%
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-123.3%
ROIC (approx.)—
Asset turnover0.19x

Leverage & solvency

Liabilities / assets547.3%
Debt / equity—
Current ratio0.04x
Interest coverage-1.91x

Cash quality & payout

Operating cash flow / net income0.01x
Accruals ratio-122.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$1.36M$820,137$0$0$0
Cost of revenue$3.45M$3.76M$0——
Gross profit-$2.08M-$2.93M$0——
SG&A expense$489,641$145,713$703,596$2.23M$852,645
Operating income-$3.35M-$3.63M-$1.58M-$5.21M-$2.99M
Interest expense$1.96M$2.26M$1.69M$2.29M$1.51M
Pretax income———-$8.53M-$8.83M
Income tax$0$0$0$0$0
Net income-$11.13M-$9.91M$3.69M-$8.53M-$8.83M
EBITDA—-$3.63M-$1.45M-$4.92M-$2.99M
EPS (basic)———0.040.12
EPS (diluted)-0.02-0.020.010.040.12
Weighted avg. shares (diluted)662.50M625.28M308.94M211.04M74.69M
Balance sheet
Cash & equivalents$1,804$2,156$650$2,317$27,767
Receivables$164,430$1,747$0——
Inventory$1.12M$996,250$1.13M——
Current assets$1.31M$1.02M$1.20M$100,014$29,538
PP&E, net$127,029$137,237$161,540$107,780$6,032
Total assets$7.02M$10.84M$11.75M$5.41M$114,330
Current liabilities$31.59M$25.75M$18.73M$17.43M$13.04M
Total liabilities$37.17M$30.65M$23.90M$22.76M$13.04M
Shareholders' equity-$30.15M-$19.81M-$12.15M$17.34M-$12.93M
Shares outstanding662.50M662.50M440.75M274.12M125.51M
Cash flow statement
Operating cash flow-$789,102-$1.70M-$2.27M-$1.45M-$2.41M
Capital expenditure$5,519$0$80,634——
Free cash flow-$794,621-$1.70M-$2.36M——
Investing cash flow$794,269$1.70M-$80,634-$115,998$493,623
Financing cash flow-$5,519$0$2.35M$1.40M$1.34M
Depreciation & amortization—$0$127,847$294,934$2,708
Stock-based compensation———$180,979$363,050

Free plan shows the latest 5 periods; Pro shows all 17 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.